Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration

Int J Antimicrob Agents. 2016 Sep;48(3):342-3. doi: 10.1016/j.ijantimicag.2016.06.005. Epub 2016 Jul 8.

Authors

Joseph L Kuti¹, Islam M Ghazi¹, Richard Quintiliani Jr², Eric Shore³, David P Nicolau⁴

Affiliations

¹ Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA.
² Division of Infectious Diseases, Department of Medicine, Hartford Hospital, Hartford, CT, USA.
³ Division of Pulmonary and Critical Care Medicine, Department of Medicine, Hartford Hospital, Hartford, CT, USA.
⁴ Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA; Division of Infectious Diseases, Department of Medicine, Hartford Hospital, Hartford, CT, USA. Electronic address: david.nicolau@hhchealth.org.

PMID: 27451086
DOI: 10.1016/j.ijantimicag.2016.06.005

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Anti-Infective Agents, Urinary / administration & dosage*
Anti-Infective Agents, Urinary / pharmacokinetics
Cephalosporins / administration & dosage*
Cephalosporins / pharmacokinetics
Chromatography, High Pressure Liquid
Critical Illness
Drug Resistance, Multiple, Bacterial*
Hemofiltration*
Humans
Male
Penicillanic Acid / administration & dosage
Penicillanic Acid / analogs & derivatives*
Penicillanic Acid / pharmacokinetics
Plasma / chemistry
Pseudomonas Infections / drug therapy*
Pseudomonas Infections / microbiology
Pseudomonas aeruginosa / drug effects*
Pseudomonas aeruginosa / isolation & purification
Tazobactam
Treatment Outcome
United States
beta-Lactamase Inhibitors / administration & dosage*
beta-Lactamase Inhibitors / pharmacokinetics

Substances

Anti-Infective Agents, Urinary
Cephalosporins
beta-Lactamase Inhibitors
ceftolozane, tazobactam drug combination
Penicillanic Acid
Tazobactam